Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-25
2005-01-25
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S356000, C544S365000, C546S321000
Reexamination Certificate
active
06846826
ABSTRACT:
Certain 1,4-dihydropyridine compounds, useful as adrenergic blocking agents and as calcium channel blocking agents, the compounds having the formulawherein R1is hydrogen, halogen, C1-6-alkyl, or C1-6-alkoxy, R3is hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy, or CF3(CH2)nO— wherein n is1, 2, or3, and R5is —NHCH2CH2O— or —N(CH2CH2)2N—.
REFERENCES:
patent: 20020156109 (2002-10-01), Chen
patent: 2000-86633 (2000-03-01), None
Khadikar et al. Indian Journal of Chemistry, vol. 33B, pp. 451-454 (1994).*
Asano et al., “Pharmacological Profiles of YM-16151-1 and Its Optical Isomers: A Novel Calcium Entry Blocking and Selective Beta-1 Adrenoceptor Blocking Agent,” Journal of Pharmacology and Experimental Therapeutics, vol. 254, No. 1, pp. 204-211.
Ciaraldi et al., “Hormone Action at the Membrane Level—VII: Adrenergic Receptors in Rat Heart and Adipocytes and Their Modulation by Thyroxine,” Biochemica et Biophysica Acta, vol. 541, 1978, pp. 334-346.
Chen et al., “Capsinolol: the first β-adrenoceptor blocker with an associated calcitonin gene-related peptide releasing activity in the heart,” British Journal of Pharmacology, vol 119, 1996, pp. 7-14.
Chen et al., “Eugenolol: An Eugenol-Derived β-Adrenoceptor Blocker with Partial β2-Agonist and Calcium Mobilization Inhibition Associated Vasorelaxant Activities,” Drug Development Research, vol. 40, 1997, pp. 239-250.
Chen et al., “Xanthonolol: A Calcium Channel and Beta-Adrenoceptor Blocker with Vasodilating Properties,” Gen. Pharmac., vol. 24, No. 6, 1993, pp. 1425-1433.
Huang et al., “Eugenodilol: A Third-Generation β-Adrenoceptor Blocker, Derived from Eugenol, with α-Adrenoceptor Blocking and β2-Adrenoceptor Agonist-Associated Vasorelaxant Activities,” Journal of Cardiovascular Pharmacology, vol. 34, 1999, pp. 10-20.
Huang et al., “Ferulidilol: A Vasodilatory and Antioxidant Adrenoceptor and Calcium Entry Blocker, with Ancillary β2-Agonist Activity,” Drug Development Research, vol. 47, 1999, pp. 77-89.
Liang et al., “Labedipinedilol-A: A Vanilloid-Based α/β-Adrenoceptor Blocker with Calcium Entry Blocking and Long-Acting Antihypertensive Properties,” Drug Development Research, vol. 49, 2000, pp. 94-108.
Lin et al., “Vasomolol: An Ultra Short-Acting and Vasorelaxant Vanilloid Type β1-Adrenoceptor Antagonist,” Journal of Cardiovascular Pharmacology, vol. 28, 1996, pp. 149-157.
O'Donnell et al., “The Contribution of Extraneural Uptake to the Trachea-Blood Vessel Selectivity of β-Adrenoceptor Stimulants in vitro in Guinea-Pigs,” Br. J. Pharmac., vol. 57, 1976, pp. 369-373.
O'Donnell et al., “The Importance of Choice of Agonist in Studies Designed to Predict β2:β1Adrenoceptor Selectivity of Antagonists from pA2Values on Guinea-Pig Trachea and Atria,” Naunyn-Schmiedeberg's Arch. Pharmacol., vol. 308, 1979, pp. 183-190.
Porzig et al., “Competitive and Non-Competitive Interactions Between Specific Ligands and Beta-Adrenoceptors in Living Cardiac Cells*,” Nauyn-Schmiedeberg's Arch. Pharmacol., vol. 321, 1982, pp. 89-99.
Ruffolo Jr. et al., “Recent Observations with β-Adrenoceptor Blockade: Beneficial Effects in Hypertension and Heart Failure,” American Journal of Hypertension, vol. 11, 1998, pp. 9S-14S.
Sheu et al., “Vanidilol: A vanilloid-Type Vasorelaxant and Ocular Hypertensive Beta-Adrenoceptor Blocker with Partial Beta-2-Agonist Activity,” Pharmacology, vol. 54, 1997, pp. 211-224.
Yamamoto et al., “Pharmacologic Characterization of FR172516: A New Combined Calcium Channel-Blocking and β-Adrenoceptor-Blocking Agent,” Journal of Cardiovascular Pharmacology, vol. 33, 1999, pp. 587-594.
Yeh et al., “Isoeugenodilol: A Vasorelaxant α/β-Adrenoceptor Blocker with Antioxidant Activity,” Drug Development Research, vol. 51, 2000, pp. 29-42.
Yeh et al., “Third-Generation Dihydropyridine-Type Calcium Channel Blocker Labedipinedilol-B Displays α/β-Adrenoceptor Blocking Activities,” Drug Development Research, vol. 52 2001, pp. 462-474.
Yeh et al., “Vanidipinedilol: A Vanilloid-Based β-Adrenooceptor Blocker Displaying Calcium Entry Blocking and Vasorelaxant Activities,” Journal of Cardiovascular Pharmacology, vol. 35, 2000, pp. 51-63.
Wu et al., “A Highly Selective β1-Adrenergic Blocker with Partial β2Agonist Activity Derived from Ferulic Acid, an Active Component ofLigusticum wallichiiFranch,” Journal of Cardiovascular Pharmacology, vol. 31, 1998, pp. 750-757.
Wu et al., “Zingeronolol: A Newly Developed β-Adrenergic Blocking Agent Derived from Zingerone, A Pungent Principle of Ginger,” Asia Pacific Journal of Pharmacology, vol. 11, 1996, pp. 5-12.
Shibasaki et al. Amtianginal Effects of YM430, a Novel Calcium Entry-Blocking and β-Adrenoceptor-Blocking Agent in Several Experimental Angina Models, Gen. Pharmac. vol. 29, No. 4, pp. 545-550, 1997.
Yamamoto et al., Pharmacologic Characterization of FR172516: A New Combined Calcium Channel-Blocking and β-Adrenoceptor-Blocking Agent, Journal of Cardiovascular Pharmacology pp. 587-594, vol. 33, No. 4, 1999.
Yeh et al., Vanidipinedilol: A Vanilloid-Based β-Andrenoceptor Blocker Displaying Calcium Entry Blocking and Vasorelaxant Activities, Journal of Cardiovascular Pharmacology, vol. 35, No. 1, 2000. pp. 51-63.
Buhler, Cardiovascular care with the new T-type clacium channel antagonist: possible role of attendant sympathetic nervous system inhibition, Journal of Hypertension 1997, vol. 15, p. 3-7.
Ruffolo Jr. et al., Carvedilol: A Novel Cardiovascular Drug with Multiple Actions, Cardiovascular Drug Reviews, vol. 10, No. 2, pp. 127-157, 1992.
Bernhardt Emily
Birch & Stewart Kolasch & Birch, LLP
Chen Ing-Jun
Lin Tong-Ho
LandOfFree
Phenoxypropanol connected with phenylpiperazine and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenoxypropanol connected with phenylpiperazine and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenoxypropanol connected with phenylpiperazine and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3409508